NUMORPHAN (oxymorphone) Suppository is indicated for the relief of moderate to severe pain.

NUMORPHAN (oxymorphone) Injection is indicated for the relief of moderate to severe pain. It is also indicated for preoperative medication, for support of anesthesia, for obstetrical analgesia, and for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction.

Smaller doses of NUMORPHAN (oxymorphone) than those recommended below should be used for debilitated and elderly patients and those with severe liver disease.

Usual Adult Dosage of NUMORPHAN (oxymorphone) Injection

Subcutaneous or intramuscular administration: initially 1 mg to 1.5 mg, repeated every 4 to 6 hours as needed. Intravenous: 0.5 mg initially. In non debilitated patients the dose can be cautiously increased until satisfactory pain relief is obtained. For analgesia during labor 0.5 mg to 1 mg intramuscularly is recommended.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Usual Adult Dosage of NUMORPHAN (oxymorphone) Rectal Suppositories

One suppository, 5 mg, every 4 to 6 hours. In non debilitated patients the dose can be cautiously increased until satisfactory pain relief is obtained.

For Injection

DEA Order Form Required

1 mg/mL 1 mL ampuls (paraben/sodium dithionite-free) (box of 10) NDC 63481-444-10
1.5 mg/mL 10 mL multiple dose vials (sodium dithionite-free) (box of 1) NDC 63481-445-01

Store at 25°C (77°F);excursions permitted to 15°-30°C (59°-86°F).[See USP Controlled Room Temperature.] Protect from light.

For Rectal Suppositories

DEA Order Form Required

5 mg Wrapped in gold foil (box of 6)NDC 63481-761-06

Store under refrigeration 2° - 8°C (36°- 46°F).

Manufactured for: Endo Pharmaceuticals Inc., Chadds Ford, Pennsylvania 19317. NUMORPHAN® (oxymorphone) is a Registered Trademark of Endo Pharmaceuticals Inc. NARCAN® is a Registered Trademark of Endo Pharmaceuticals Inc. April, 2004. FDA revision date: 9/25/2000

Last reviewed on RxList: 6/24/2008
This monograph has been modified to include the generic and brand name in many instances.